Figure 4.

β1 Integrin Signaling Increases MON Cell Proliferation at Early Stages of Differentiation

(A and B) Western blot analysis (A) and quantification of protein expression level (B) of phospho-FAK in ORG, MON and MON treated with either an isotype control antibody (Iso Ctrl) or an anti-β1-integrin antibody (anti- β1ITG) at TD2 and TD11.

(C and D) Representative images (C) and stereological quantification (D) of immunostaining with the proliferative marker Ki67 and the neuron-specific marker TUJ1 at TD2 under the conditions described above.

(E) Relative expression level of a subset of genes from the Neuronal Cell Fate list (Table S4A) at TD2.

(F and G) Western blot analysis (F) and quantification of protein expression level (G) of TBR1, DCX, and NEUROG2 at TD11. GAPDH was used as loading control.

Data are expressed as mean ± SEM of n = 3 preparations per condition (ORGs or MONs with or without each antibody) from one iPSC line. ^∗p < 0.05, ^∗∗∗p < 0.01, ^∗∗∗∗p < 0.001; MONs versus ORGs; #p < 0.05 MONs + anti-ITGβ1 versus MONs + Isotype Ctrl. One-way ANOVA with Tukey multiple comparisons test. See also Figure S4.